...of the patent, plus damages. GSK gained the '023 patent through its 2008 acquisition of Genelabs Technologies Inc....

...Inc. (now part of Roche ), Idenix Pharmaceuticals Inc. , Human Genome Sciences Inc. , Genelabs Technologies Inc....
...the time, Genelabs' lead program was a preclinical NS5A inhibitor. Masow said the collaboration with Genelabs...

...is marketed for DNA sequencing. GlaxoSmithKline gained the '023 patent through its 2008 acquisition of Genelabs Technologies Inc....

...the PNAS article will be suitable for repurposing for HCV." Concurrent with its acquisition of Genelabs Technologies Inc....
...doi:10.1038/scibx.2010.3 Published online Jan. 7, 2010 Companies and Institutions Mentioned Debiopharm S.A. , Lausanne, Switzerland Genelabs Technologies Inc....

...Business: Infectious Hired: Frederick Driscoll as VP and CFO, formerly CFO, president and CEO of Genelabs Technologies Inc. WIR...

...Infectious Hired: Roy Wu as SVP of business development, formerly VP of business development at Genelabs Technologies Inc. WIR...

...other large pharmas that have shown interest in NS5B inhibitors. Through its January acquisition of Genelabs Technologies Inc....
...that was in preclinical development. GL59728 is partnered with Novartis under a 2006 deal with Genelabs...

...GlaxoSmithKline completed its previously announced tender offer for Genelabs, acquiring about 39.3 million shares (89%) at...
...remaining shares at the same price through a short-form merger (see BioCentury, Nov. 3, 2008). Genelabs Technologies Inc....

...Genelabs. At Dec. 29, there were 36.4 million shares tendered (see BioCentury, Nov. 3, 2008). Genelabs Technologies Inc....

...Genelabs. At Dec. 12, there were 35.1 million shares (79%) tendered (see BioCentury, Nov. 3). Genelabs Technologies Inc....